<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1905210736
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Saizen
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SOMATROPIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in cartridge
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Cartridge
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        512.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MERCK SERONO SPA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MERCK SERONO SPA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SERONO EUROPE LTD
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H01AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Saizen is a growth hormone. Saizen&#39; s main action is to increase growth in children and adolescents and to treat adults with growth hormone deficiency.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The growth hormone (somatropin) contained in Saizen is almost the same as human&rsquo;s natural growth hormone except that it is made outside the body by a process called &ldquo;recombinant DNA technology&rdquo; (genetic engineering).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Saizen is used:</p><p dir="ltr">&nbsp;</p><p dir="ltr">In children and adolescents:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the treatment of children with short stature who have failed to grow because their body produces no growth hormone or insufficient levels of growth hormone</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the treatment of girls who have failed to grow due to gonadal dysgenesis (also referred to as Turner syndrome), confirmed by a test on the chromosomes</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the treatment of pre-pubertal children who have failed to grow due to chronic renal failure, a condition in which kidneys are damaged</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the treatment of growth problems in children who were born small and who have not reached normal height by the age of 4&nbsp;years or later.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In adults:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the treatment of adults with a marked lack of growth hormone (growth hormone deficiency).<br />This therapy is given to adults who have a serious growth hormone deficiency that has been medically diagnosed by a test.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The doctor or pharmacist will be able to explain why this medicine has been given to you or to your child.</p><p dir="ltr">&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Do not use Saizen</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you (or your child) are allergic (hypersensitive) to somatropin or any of the other ingredients of this medicine (listed in section 6).</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have been told that your child&rsquo;s bones have stopped growing and that he/she has therefore reached his/her final height.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an active tumour (cancer). Tumours must be inactive, and you must have finished your anti-tumour treatment before you start your treatment with Saizen.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you (or your child) have diabetes and are suffering from an associated eye disease (proliferative or pre-proliferative diabetic retinopathy).</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or your child have an acute critical illness, suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure or similar conditions.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment with Saizen has to be stopped in children with chronic kidney disease at time of kidney transplantation.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Warnings and precautions</strong></p><p dir="ltr">Talk to your doctor before using Saizen.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Saizen therapy should be carried out under regular guidance of a doctor who is experienced in the diagnosis and management of patients with growth hormone deficiency.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Shortly after Saizen is given, you (or your child) may feel shaky or light-headed due to low blood sugar levels. These feelings will quickly disappear. Your (or your child&rsquo;s) blood sugar levels may then rise above normal 2‑4&nbsp;hours after administration. Since treatment with growth hormone can alter how your body handles sugar, your (or your child&rsquo;s) sugar levels will be tested regularly by a doctor. Somatropin may cause your (or your child&rsquo;s) blood sugar to increase.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you (or your child) are diabetic or a member of your family has diabetes, your doctor will monitor closely your blood sugar level and may adjust the treatment for diabetes while you are being treated with Saizen.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Please be aware that you may need regular eye tests after having this medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Saizen may affect how your thyroid works. Your doctor may test your blood for levels of thyroid hormones and prescribe another hormone if you (or your child) are found to have developed a lack of thyroid hormone.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you (or your child) are using corticosteroids, you should consult your doctor regularly, as you may need adjustment of your corticosteroid or your Saizen dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Saizen may cause fluid retention in adult patients. This may appear as swelling and joint or muscle pain. If you feel these symptoms tell your doctor who may decide to adjust your dose of Saizen.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you have had a tumour in your childhood and were treated with Saizen, there is an increased risk to develop a new tumour. If in the past you (or your child) have had a condition affecting the brain, e.g. a tumour, the doctor will examine you (or your child) regularly to check that this has not come back again.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Rarely Saizen may cause an inflammation of the pancreas, which causes severe pain in the abdomen and back. Please consider this especially if your child suffers from stomachache and contact your doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr">An increase in sideways curvature of the spine (scoliosis) may progress in any child during rapid growth. During treatment with Saizen, your doctor will check you (or your child) for signs of scoliosis.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Some patients may develop swelling of the brain, while taking Saizen. If you (or your child) suffer from a bad or recurrent headache, problems with your eyesight, feel sick (nausea) and/or being sick (vomiting), contact your doctor immediately. In this case it may be necessary to stop the growth hormone treatment, although treatment may be re-started at a later date. If the symptoms of brain swelling come back, treatment with Saizen should be discontinued.</p><p dir="ltr">&nbsp;</p><p dir="ltr">When the medicine is injected into the same place over a long period of time, it can cause damage to this area. It is therefore important to keep changing the injection site. Your doctor or pharmacist can speak to you about which parts of the body should be used (see section 3 How to use Saizen).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Some children with growth hormone deficiency have developed leukaemia (increased number of white blood cells), whether or not they have received treatment with growth hormone. However there is no evidence that leukaemia incidence is increased in growth hormone recipients without predisposing factors. No cause and effect relationship with growth hormone treatment has been proven.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Hip problems may occur more commonly in children with hormone or kidney problems. If your child has chronic renal failure, which can occur when kidneys are damaged, he or she should be examined periodically for evidence of bone disease. It is uncertain whether the bone disease in children with hormone or kidney problems is affected by growth hormone therapy. X‑rays of the hip should be obtained prior to initiating therapy. If your child develops a limp or complains of hip or knee pain while being treated with Saizen, tell your doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment with Saizen will be stopped in children with chronic kidney failure at the time of kidney transplant.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Saizen is not indicated for the long-term treatment of paediatric patients who have growth failure due to genetically confirmed Prader‑Willi syndrome, unless they also have a diagnosis of growth hormone deficiency. There have been reports of sleep apnoea and sudden death after initiating therapy with growth hormone in paediatric patients with Prader‑Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnoea, or unidentified respiratory infection.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Growth hormone should generally not be used by people who are seriously ill.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you do not respond to the therapy with Saizen, you may have developed antibodies to growth hormone. Your doctor will conduct appropriate tests to determine this.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you are over 60&nbsp;years old or if you are taking Saizen for a long time<sup> </sup>you should be examined more frequently by your doctor. As there is less experience both in the treatment of older people and in prolonged treatment with Saizen, special care is required.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">Other medicines and Saizen</p><p dir="ltr">Tell your doctor or pharmacist if you (or your child) are using, have recently used or might use any other medicines.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you (or your child) are using corticosteroids, it is important to tell the doctor or pharmacist. These medicines could interact with Saizen and therefore your doctor may need to adjust the dose of these medicines or your Saizen dose. Corticosteroids are used to treat several illnesses including asthma, allergies, kidney rejection and rheumatoid arthritis.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you have a replacement therapy with oral oestrogens, it may reduce the effect of Saizen on growth. Therefore, your doctor may need to adjust your Saizen dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you are treated with sex hormones, medicines to control epilepsy (anticonvulsants) or cyclosporine (a medicine that weakens the immune system after transplantation), you should tell you doctor as the dose of these medicines may need to be adjusted.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Pregnancy and breast feeding</p><p dir="ltr">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p dir="ltr">There is currently insufficient evidence from human studies on the safety of growth hormone treatment during pregnancy and breast feeding. Saizen should be discontinued, if pregnancy occurs.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Driving and using machines</p><p dir="ltr">No studies on the effects of Saizen on the ability to drive and use machines have been performed.</p><p dir="ltr">Somatropin-containing products have no influence on the ability to drive and use machines.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Important information about some of the ingredients of Saizen</strong></p><p dir="ltr">This medicine contains less than 1 mmol sodium (23 mg) per cartridge, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dosage</p><p dir="ltr">&nbsp;</p><p dir="ltr">The dose and frequency of administration of Saizen will be decided by your doctor and will depend on your (or your child&rsquo;s) body weight or body surface area.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">It is recommended that Saizen be administered at bedtime.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Children and adolescents:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short stature due to a lack of, or insufficient levels of natural growth hormone:<br />0.7‑1.0&nbsp;mg/m<sup>2 </sup>body surface area each day or 0.025‑0.035&nbsp;mg/kg body weight each day by subcutaneous administration (under the skin).</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth failure in girls due to gonadal dysgenesis (Turner syndrome):<br />1.4&nbsp;mg/m<sup>2</sup> body surface area per day or 0.045‑0.050&nbsp;mg/kg body weight each day by subcutaneous administration (under the skin).<br />If your daughter is treated for Turner syndrome and she receives non-androgenic anabolic steroids as well, growth response may be enhanced. Ask your doctor or pharmacist if you are not sure about these drugs.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth failure in pre-pubertal children due to chronic renal failure, a condition in which kidneys are damaged:<br />1.4&nbsp;mg/m<sup>2</sup> body surface area, approximately equal to 0.045‑0.050&nbsp;mg/kg body weight each day by subcutaneous administration (under the skin).</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth problems in children who were born small:<br />1&nbsp;mg/m<sup>2</sup> body surface area, approximately equal to 0.035&nbsp;mg/kg body weight each day by subcutaneous administration (under the skin).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Adults:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth hormone deficiency in adults:<br />At the start, low doses of 0.15‑0.30&nbsp;mg each day are recommended by subcutaneous injection (under the skin). The dose will be adjusted in stages by your doctor. The recommended final dose of growth hormone rarely exceeds 1.0&nbsp;mg/day. In general, the lowest efficacious dose that works for you should be administered. If you are older or overweight, a lower dose may be necessary.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Method and route of administration</p><p dir="ltr">&nbsp;</p><p dir="ltr">The dose and frequency of administration of Saizen will be decided by your doctor and will depend on your (or your child&rsquo;s) size or body weight. In general, Saizen should be administered each day by subcutaneous injection (under the skin).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Important information</p><p dir="ltr">For administration of Saizen, please read the following instructions carefully.</p><p dir="ltr">When the medicine is injected into the same place every time for a long time, it can cause damage. It is important to keep changing the place where you have your injection. Your doctor or pharmacist can speak to you about which part of the body you should use. Do not use any areas in which you feel lumps, firm knots, depressions, or pain; talk to your doctor or pharmacist about anything you find. Clean the skin at the injection site with soap and water.</p><p dir="ltr"><strong><em>&nbsp;</em></strong></p><p dir="ltr">The cartridge containing the solution of Saizen is ready to be used for administration with your easypod auto-injector or aluetta pen injector.</p><p dir="ltr">Each Saizen cartridge presentation is colour coded and must be used with the matching colour coded aluetta pen injector to give the correct dose. The cartridge containing 6 mg somatropin (blue) must be used with the aluetta pen injector 6 (blue).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Place all elements needed for the injection of the solution on a clean surface and wash your hands with soap and water.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The solution should be clear to slightly opalescent with no particles and without visible signs of deterioration. If the solution contains particles, it must not be injected.</p><p dir="ltr">&nbsp;</p><p dir="ltr">How to perform your daily self-administration of Saizen</p><p dir="ltr">For instructions on how to load the cartridge into the easypod auto-injector or aluetta pen injector and inject the solution of Saizen, please carefully read the corresponding instruction manual provided with each injector. Intended users of easypod are primarily children starting from the age of 7 up to adults. Use of the devices by children should always be made under adult&rsquo;s supervision.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Duration of treatment</p><p dir="ltr">Your child should stop using this treatment when he or she reaches a satisfactory adult height or his or her bones cannot grow any longer, as assessed by his or her doctor. Treatment with Saizen will be stopped in children with chronic kidney failure at the time of kidney transplant.</p><p dir="ltr">In adults a lack of growth hormone is a lifelong condition and it should be treated accordingly by your doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you use more Saizen than you should</p><p dir="ltr">If you inject too much Saizen, you should tell your doctor as it may be necessary to change slightly the dose to make up for this. Injecting too much can lead to changes in blood sugar levels which could mean that you (or your child) will feel shaky and light-headed. If this happens contact your doctor as soon as possible.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you forget to use Saizen</p><p dir="ltr">If you miss a dose, tell your doctor as it may be necessary to slightly change the dose to make up for this.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you stop taking Saizen</p><p dir="ltr">Do not stop taking Saizen without speaking with your doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Tell your doctor immediately if you experience strong and recurrent headaches associated with feeling sick (nausea), vomiting or sight disturbances. These are symptoms of a side effect called benign intracranial hypertension and it is uncommon.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Side effects may occur with certain frequencies, which are defined as follows:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very common: may affect more than 1 in 10 people</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common: may affect up to 1 in 10&nbsp;people</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uncommon: may affect up to 1 in 100&nbsp;people</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rare: may affect up to 1 in 1,000&nbsp;people</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very rare: may affect up to 1 in 10,000 people</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not known: frequency cannot be estimated from the available data.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">Common side effects:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reactions at the injection site such as e.g. redness, itching, swelling, rash, hives, pain, inflammation, bleeding, abnormal collection of blood outside of a blood vessel (haematoma). If this appears to be particularly troublesome, you should discuss this with your doctor.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Local loss of the fat tissue under the skin, which can be avoided if you change the injection site.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carpal tunnel syndrome in adults that is characterised by persistent stinging, burning sensation, pain and/or numbness in the fingers which affect particularly the thumb, index and sometimes also middle and ring finger.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid retention: peripheral oedema (swelling), muscle pain, numbness and tingling, joint pain, and joint disorders in adult users. These side-effects appear usually early in the treatment, are short-lived and depend on the dose.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Isolated) headache.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Uncommon side effects:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Benign intracranial hypertension (increased intracranial pressure around the brain characterised by headache, nausea, vomiting, double vision and other visual symptoms).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carpal tunnel syndrome in children that is characterised by persistent stinging, burning sensation, pain and/or numbness in the fingers which affect particularly the thumb, index and sometimes also middle and ring finger.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid retention: peripheral oedema (swelling), muscle pain, numbness and tingling, joint pain, and joint disorders in children. These side-effects appear usually early in the treatment, are short-lived and depend on the dose.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast enlargement (one or both sides may be affected).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Very rare side effects:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slipped capital femoral epiphysis (a hip problem that starts if the growing end of the thigh bone slips from the ball of the hip joint) and avascular necrosis of the femoral head. If your child shows an unexplained limp and hip or knee pain, please contact your doctor or pharmacist.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth hormone treatment may reduce the levels of thyroid hormone. This can be tested by your doctor and if necessary your doctor will prescribe the adequate treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Side effects with an unknown frequency:</p><p dir="ltr">You (or your child) can experience allergic reactions due to the treatment with Saizen.</p><p dir="ltr">&nbsp;</p><p dir="ltr">You (or your child) can experience increased insulin levels (hyperinsulinism) as muscle, fat, and liver cells do not respond properly to insulin during growth hormone treatment (insulin resistance). This condition can result in high blood sugar levels (hyperglycaemia).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Rarely an inflammation of the pancreas has been reported in patients treated with growth hormone.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Leukaemia has been reported in a small number of growth hormone deficiency patients, some of whom have been treated with somatropin. However, there is no evidence that leukaemia incidence is increased in growth hormone recipients without predisposing factors.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Very rarely a patient could develop antibodies (type of protein that helps protect the body) to somatropin. These are usually not associated with any side effects and do not usually interfere with growth.</p><p dir="ltr"><strong>&nbsp;</strong></p><p>.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep this medicine out of the sight and reach of children.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not use Saizen after the expiry date which is stated on the cartridge after EXP. The expiry date refers to the last day of that month.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Store the unused Saizen cartridge in a refrigerator (2&deg;C‑8&deg;C) in the original package to protect from light. Do not freeze.</p><p dir="ltr">&nbsp;</p><p dir="ltr">After first injection, use within 28&nbsp;days.</p><p dir="ltr">&nbsp;</p><p dir="ltr">After first injection, the Saizen cartridge, the easypod auto-injector containing the Saizen cartridge or the aluetta pen injector containing the Saizen cartridge has to be stored in a refrigerator (2&deg;C‑8&deg;C) for a maximum of 28 days.</p><p dir="ltr">&nbsp;</p><p dir="ltr">When using the easypod auto-injector or the aluetta pen injector, the cartridge is kept in the device. &nbsp;&nbsp;Protect the used cartridge from light.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">&nbsp;</p><p dir="ltr">The active substance is somatropin (recombinant human growth hormone) 6&nbsp;mg<em>.</em></p><p dir="ltr">The other ingredients are sucrose, poloxamer&nbsp;188, phenol, citric acid (for pH adjustment), sodium hydroxide (for pH adjustment), water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Saizen 5.83 mg/ml is a clear to slightly opalescent solution for injection in a pre-filled cartridge (type 1 glass) with a plunger stopper (rubber) and a crimp cap (aluminium and rubber), containing a nominal value of 1.03 ml solution (6 mg somatropin). The cartridge containing 6 mg somatropin is marked with a coloured label (blue).

Pack sizes of 1 and 5 cartridges.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder&nbsp; </strong></p><p><strong>&nbsp;</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Merck Serono Limited</p><p dir="ltr">Bedfont Cross, Stanwell road</p><p dir="ltr">Felltham, Middlesex, TW14 8NX</p><p dir="ltr">Felltham, United Kingdom</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Manufacturer </strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">Merck Serono S.p.A</p><p dir="ltr">Zone industrielle de Modugno,</p><p dir="ltr">70026 Modugno (Bari),</p><p dir="ltr">Bari, Italy <strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in April 2020  
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">سيزن عبارة عن هرمون نمو. يعمل سيزن بشكل رئيسي على زيادة النمو لدى الأطفال والمراهقين وعلاج البالغين المصابين بنقص هرمون النمو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وهرمون النمو (سوماتروبين) الموجود في سيزن هو هرمون النمو البشري نفسه تقريبًا باستثناء أنه مصنوع خارج الجسم البشري من خلال عملية تُدعى &quot;تقنية الحمض النووي المأشوب&quot; (الهندسة الجينية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُستعمل سيزن:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">للأطفال والمراهقين:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج الأطفال المصابين بقصر القامة والذين عجزوا عن النمو لأن جسمهم لا ينتج هرمون النمو مطلقًا أو ينتجه بكميات غير كافية</p><p dir="RTL">&nbsp;</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في علاج الفتيات اللواتي عجزن عن النمو نتيجة خلل تكوّن الغدد التناسلية (ويُسمى أيضًا باسم متلازمة تيرنر)، وتم تأكيد تشخيص إصابتهم بهذه الحالة باختبار على الصبغيات</p><p dir="RTL">&nbsp;</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في علاج الأطفال قبل سن البلوغ والذين عجزوا عن النمو نتيجةً للفشل الكلوي المزمن، وهي حالة تحدث عندما تصاب الكليتان بتلف</p><p dir="RTL">&nbsp;</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في علاج مشكلات النمو لدى الأطفال الذين وُلدوا بحجم أقل من الطبيعي ولم يبلغوا الطول الطبيعي حتى عامهم الرابع أو بعد ذلك</p><p dir="RTL">&nbsp;</p><p dir="RTL">للبالغين:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في علاج البالغين المصابين بنقص واضح في هرمون النمو (نقص هرمون النمو). يُعطى هذا العلاج للبالغين المصابين بنقص خطير في هرمون النمو ممن تأكد تشخيص حالتهم طبيًا من خلال اختبار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستطيع الطبيب أو الصيدلي أن يشرح لك سبب وصف هذا الدواء لك أو لطفلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل سيزن</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة إصابتك (أو إصابة طفلك) بالحساسية (فرط الحساسية) لسوماتروبين أو أيّ من المكونات الأخرى لهذا الدواء (والمذكورة في القسم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان الأطباء قد أخبروك من قبل أن عظام طفلك قد توقفت عن النمو وأنه قد بلغ طوله النهائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بورم (سرطان) نشِط. يجب أن تكون الأورام غير نشِطة وأن تكون قد أنهيت علاجك المضاد للأورام قبل بدء علاجك بسيزن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة إصابتك (أو إصابة طفلك) بالسكري مع وجود مرض بالعين بسبب السكري (اعتلال الشبكية السكري التكاثري أو ما قبل التكاثري).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة إصابتك أنت أو طفلك بمرض حاد حرج أو مضاعفات بعد الخضوع لعملية القلب المفتوح أو عملية جراحية في البطن أو رضوح متعددة نتيجة حادث أو فشل تنفسي حاد أو ما إلى ذلك من الحالات المشابهة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب إيقاف العلاج بسيزن لدى الأطفال المصابين بمرض مزمن في الكلى في وقت إجراء زرع الكلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">استشر طبيبك قبل استخدام سيزن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يتم العلاج بسيزن في ظل توجيه منتظم من طبيب ذي خبرة في تشخيص نقص هرمون النمو والتعامل مع حالاته.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد تناول سيزن بوقت قصير، قد تشعر (أو يشعر طفلك) ببعض الرجفة أو الدوار نتيجة تدني مستويات السكر في الدم، ولكن هذا الشعور يزول بسرعة. قد ترتفع مستويات السكر في الدم لديك (أو لدى طفلك) إلى أعلى من المستوى الطبيعي بعد مرور ساعتين إلى 4 ساعات من تناول الدواء. بما أن العلاج بهرمون النمو قد يغير طريقة تعامل جسمك مع السكر، فسيفحص الطبيب مستويات السكر في دمك (أو دم طفلك) بانتظام. قد يؤدي سوماتروبين إلى ارتفاع مستويات السكر في دمك (أو دم طفلك).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت أنت (أو طفلك) مصابين بالسكري أو كان فرد من عائلتك مصاب بالسكري، فسيتابع طبيبك مستويات السكر في دمك متابعة دقيقة وقد يعدل علاج السكري في أثناء علاجك بواسطة سيزن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى العلم أنك قد تحتاج إلى الخضوع لفحص للعينين بعد تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤثر سيزن على طريقة عمل غدتك الدرقية. قد يجري لك طبيبك تحليل دم لقياس مستويات هرمون الغدة الدرقية ويصف هرمونًا آخر إذا اكتشف إصابتك (أو إصابة طفلك) بنقص هرمون الغدة الدرقية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تستخدم (أو يستخدم طفلك) الستيرويدات القشرية، فيجب استشارة الطبيب بانتظام، لأن جرعة الستيرويدات القشرية أو سيزن قد تحتاج للتعديل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي سيزن إلى احتباس السوائل لدى المرضى البالغين. قد يظهر ذلك في شكل ورم وألم في المفاصل أو العضلات. إذا شعرت بهذه الأعراض، فأخبر طبيبك الذي قد يقرر تعديل جرعتك من سيزن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت قد أصبت بورم في طفولتك وكان قد تم علاجك بسيزن، فإن ذلك قد يزيد من احتمالات إصابتك بورم جديد. وإذا كنت (أو كان طفلك) قد أصبتما بحالة مرضية تؤثر على المُخ، مثل ورم، فإن الطبيب سيفحصك (أو يفحص طفلك) بانتظام للتحقق من عدم عودة هذا الورم مرة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من النادر أن يسبب سيزن التهابًا في البنكرياس، وهي حالة قد تسبب ألمًا شديدًا في البطن والظهر. يُرجى وضع ذلك في الحسبان، وخاصة إذا كان طفلك يعاني من ألم في المعدة، والاتصال بطبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">قد يصاب أي طفل أثناء النمو السريع بانحناء جانبي للعمود الفقري (الجَنَف). وأثناء العلاج بسيزن، سيفحصك الطبيب (أو يفحص طفلك) لاكتشاف أي علامات للجَنَف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يصاب بعض المرضى بتورم المُخ في أثناء تناول سيزن. إذا كنت أنت (أو طفلك) تعانيان من صداع مؤلم أو متكرر أو مشكلات في الرؤية أو غثيان و/أو القيئ، فاتصل بطبيبك على الفور. في هذه الحالة، قد يتطلب الأمر إيقاف العلاج بهرمون النمو، مع إمكانية العودة إليه في وقت لاحق. يجب إيقاف العلاج بسيزن إذا عادت أعراض تورم المُخ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي حقن الدواء في المكان نفسه لفترة طويلة من الزمن إلى تضرره، ولهذا فمن الضروري تغيير مكان الحقن باستمرار. ويمكن لطبيبك أو الصيدلي أن يوضح لك أجزاء الجسم التي يجب أن تحقن فيها (راجع القسم 3 طريقة استعمال سيزن).</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعض الأطفال المصابين بنقص هرمون النمو يصابون بسرطان الدم (اللوكيميا) (تزايد عدد خلايا الدم البيضاء)، سواء كان قد تناول علاجًا بهرمون النمو أم لا. ولكن لا يوجد دليل على زيادة حدوث سرطان الدم (اللوكيميا) بين من أُعطوا هرمون النمو ولا توجد لديهم عوامل تجعلهم أكثر استعدادًا للإصابة به. كما تعذّر إثبات وجود أيّ علاقة سببية بين العلاج بهرمون النمو والإصابة بهذا السرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث مشكلات الفخذ قد تكون أكثر شيوعًا لدى الأطفال المصابين بمشكلات في الهرمونات أو في الكليتين. إذا كان طفلك مصابًا بفشل كلوي، وهي حالة تحدث في حال تضرر الكليتين، فينبغي فحصه بانتظام لاكتشاف أي علامات للإصابة بأمراض العظام. من غير المؤكد إذا ما كان العلاج بهرمون النمو يؤثر على أمراض العظام لدى الأطفال الذين يعانون من مشكلات في الهرمونات أو الكليتين. يجب تصوير الورك بالأشعة السينية قبل البدء بالعلاج. أخبر طبيبك إذا أصيب طفلك بعرج أو اشتكى من ألم في وركه أو ركبته خلال علاجه بدواء سيزن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتم إيقاف العلاج بسيزن لدى الأطفال المصابين بفشل مزمن في الكلى في وقت إجراء زرع الكلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُمنع استعمال سيزن للعلاج طويل الأجل للأطفال المصابين بقصور النمو نتيجة متلازمة بريدر-فيلي وتم تأكيد تشخيصهم بالفحوصات الجينية، ويُستثنى من ذلك الأطفال الذين تم تشخيص إصابتهم أيضًا بنقص هرمون النمو. وردت تقارير عن انقطاع التنفس في أثناء النوم والموت المفاجئ بعد بدء العلاج بهرمون النمو لدى الأطفال المصابين بمتلازمة بريدر-فيلي مع تأثرهم بعامل أو أكثر من عوامل الخطر التالية: السمنة المفرطة، سبق التعرض لانسداد مجرى الهواء العلوي أو انقطاع التنفس في أثناء النوم، أو عدوى تنفسية مجهولة النوع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وعمومًا ينبغي عدم استخدام هرمون النمو لعلاج المصابين بمرض شديد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تستجب للعلاج بسيزن، فمن المحتمل أن تكون قد نشأت لديك أجسام مضادة لهرمون النمو. وسيجري طبيبك الاختبارات اللازمة لتحديد ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تراجع طبيبك للفحص على فترات أقرب إذا كان عمرك أكثر من 60 سنة أو إذا كنت تتناول سيزن لمدة طويلة. وتحتاج مثل تلك الحالات عناية خاصة بسبب قلة الخبرة في استخدام سيزن لعلاج كبار السن أو استخدامه لفترات طويلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وسيزن</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي بأي أدوية أخرى تستعملها (أو يستعملها طفلك) أو استعملتها حديثاً أو قد تستعملها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم أن تخبر طبيبك أو الصيدلي إذا كنت تستخدم (أو كان طفلك يستخدم) الستيرويدات القشرية؛ فهذه الأدوية قد تتفاعل مع سيزن وبالتالي قد يحتاج طبيبك إلى تعديل جرعتك من هذه الأدوية أو من سيزن. تُستعمَل الستيرويدات القشرية لعلاج العديد من الأمراض بما فيها الربو، والحساسية، وحالات زرع الكلى للتغلب على رفض الجسم للكلية المزروعة، وداء المفاصل الروماتويدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة اتباعك علاجًا هرمونيًا بديلاً بأقراص الأستروجين، فقد تقلل هذه الأقراص من تأثير سيزن على النمو؛</p><p dir="RTL">ولهذا فقد يحتاج طبيبك إلى تعديل جرعتك من سيزن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">إذا كنت تخضع للعلاج بهرمونات جنسية، أو أدوية للسيطرة على الصرع (مضادات التشنجات) أو سيكلوسبورين (دواء يضعف جهاز المناعة بعد عمليات نقل الأعضاء)، فيجب أن تخبر طبيبك لأن جرعات تلك الأدوية قد تحتاج إلى تعديل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملاً أو مرضعة أو تعتقدين أنكِ قد تكونين حاملاً أو تخططين لإنجاب طفل، فاحرصي على استشارة طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ما زالت الأدلة المتوفرة حاليًا والناتجة عن الدراسات على البشر حول سلامة العلاج بهرمون النمو في أثناء الحمل والإرضاع غير كافية؛ ولهذا يجب إيقاف سيزن في حال حدوث حمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستعمال الآلات</strong></p><p dir="RTL">لم يتم إجراء أيّ دراسات حول تأثيرات سيزن على القيادة واستعمال الآلات.</p><p dir="RTL">ليس للمنتجات التي تحتوي على سوماتروبين أيّ تأثير على القدرة على القيادة واستعمال الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات مهمة حول بعض مكونات سيزن</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذه الدواء على أقل من 1 ميليمول صوديوم (23 ملغ) في الخرطوشة الواحدة، وهو ما يجعله فعليًا &quot;خالٍ من الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استعمل هذا الدواء دائمًا كما أشار عليك طبيبك تمامًا. ويجب عليك استشارة طبيبك أو الصيدلي إذا راودك أي شك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">سيحدد طبيبك جرعة سيزن وعدد مرات تناولها وسيعتمد ذلك على وزنك (أو وزن طفلك) أو مساحة سطح الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُوصى بتناول سيزن مباشرةً قبل النوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال والمراهقين:</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصر القامة نتيجةً لعدم وجود هرمون النمو الطبيعي أو عدم كفايته:</p><p dir="RTL">&nbsp;</p><p dir="RTL">من 0.7 إلى 1.0 ملغ/م<sup>2</sup> من المساحة السطحية للجسم يوميًا أو من 0.025 إلى 0.035 ملغ/كلغ من وزن الجسم يوميًا عن طريق الحقن تحت الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل النمو لدى الفتيات نتيجةً لخلل تكوّن الغدد التناسلية (متلازمة تيرنر):</p><p dir="RTL">&nbsp;</p><p dir="RTL">1.4 ملغ/م<sup>2</sup> من المساحة السطحية للجسم يوميًا أو من 0.045 إلى 0.050 ملغ/كلغ من وزن الجسم يوميًا عن طريق الحقن تحت الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت ابنتك تُعالج من متلازمة ترنر وكانت تتناول ستيرويدات ابتنائية غير أندروجينية أيضًا، فربما يتحسن النمو. اسأل طبيبك أو الصيدلي إذا كان يراودك الشك حول هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل النمو لدى الأطفال قبل سن البلوغ نتيجةً للفشل الكلوي المزمن، وهي حالة تحدث عندما تصاب الكليتان بتلف:</p><p dir="RTL">&nbsp;</p><p dir="RTL">1.4 ملغ/م<sup>2</sup> من المساحة السطحية للجسم، تساوي تقريبًا 0.045 إلى 0.050 ملغ/كلغ من وزن الجسم يوميًا عن طريق الحقن تحت الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات النمو لدى الأطفال المولودين بحجم أقل من الطبيعي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">1 ملغ/م<sup>2</sup> من المساحة السطحية للجسم، تساوي تقريبًا 0.035 ملغ/كلغ من وزن الجسم يوميًا عن طريق الحقن تحت الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">البالغون:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص هرمون النمو لدى البالغين:</p><p dir="RTL">&nbsp;</p><p dir="RTL">في البداية، يُوصى بتناول جرعات صغيرة من 0.15 إلى 0.30 ملغ يوميًا عن طريق الحقن تحت الجلد. سيقوم طبيبك بتعديل الجرعة تدريجيًا للوصول إلى الجرعة المثلى. نادرًا ما تتجاوز الجرعة النهائية الموصى بها من هرمون النمو 1.0 ملغ في اليوم. وعامة، يجب أن تتناول أقل جرعة أثبتت فعالية معك. وفي حالة كبار السن وزيادة الوزن، قد تحتاج لتناول جرعة أقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>طريقة تناول الدواء وأسلوب تناوله</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">سيحدد طبيبك جرعة سيزن وعدد مرات تناولها وسيعتمد ذلك على حجمك (أو حجم طفلك) أو وزن الجسم. وبشكل عام، يجب تناول سيزن كل يوم عن طريق الحقن تحت الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات مهمة</strong></p><p dir="RTL">اقرأ الإرشادات التالية بعناية لتناول سيزن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي حقن الدواء في المكان ذاته كل مرة ولمدة طويلة إلى الضرر؛ ولهذا فمن الضروري تغيير مكان الحقن باستمرار. ويمكن لطبيبك أو الصيدلي أن يوضح لك أجزاء الجسم التي يجب الحقن فيها. لا تستعمل أيًا من المناطق التي تشعر فيها بوجود كُتَل أو عقد صلبة أو تجاويف أو ألم؛ واستشر طبيبك أو الصيدلي إذا لاحظت أيًا من ذلك. نظف الجلد في موضع الحقن بالصابون والماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الخرطوشة التي تحتوي على محلول سيزن جاهزة للاستعمال باستخدام محاقن &quot;إيزيبود&quot; الذاتية أو قلم حقن ألوتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كل شكل من أشكال خرطوشة سيزن له لون مميز له ويجب استخدامه مع أقلام حقن ألوتا المميزة باللون نفسه لإعطاء الجرعة الصحيحة. يجب استخدام الخرطوشة التي تحتوي على 6 ملغ من سوماتروبين (زرقاء) مع قلم حقن ألوتا 6 (الأزرق).</p><p dir="RTL">&nbsp;</p><p dir="RTL">ضع كل المستلزمات المطلوبة لحقن المحلول على سطح نظيف واغسل يديك بالصابون والماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يكون المحلول صافيًا أو مائلاً إلى الإعتام قليلاً ويجب أن يخلو من أيّ جسيمات وأيّ علامات ظاهرة على التلف. يجب عدم حقن المحلول إذا كان يحتوي على جسيمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة تناول سيزن ذاتيًا كل يوم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لإرشادات طريقة تثبيت الخرطوشة في محاقن &quot;إيزيبود&quot; الذاتية أو قلم حقن ألوتا وحقن محلول سيزن، يرجى قراءة دليل الإرشادات الذي يأتي مع المحقنة المستخدمة. تُستخدم محاقن &quot;إيزيبود&quot; في الأساس للأطفال بدايةً من عمر 7 سنوات وصولاً إلى الأشخاص البالغين. ويجب أن يستعمل الأطفال الأجهزة دائمًا تحت إشراف شخص بالغ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مدة العلاج</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يتوقف طفلك عن استعمال هذا العلاج عندما يصل إلى طول مُرضٍ للبالغين أو عند الوصول إلى أقصى حد يمكن لعظامه النمو إليه، وذلك بناء على تقييم طبيبه. سيتم إيقاف العلاج بسيزن لدى الأطفال المصابين بفشل مزمن في الكلى في وقت إجراء زرع الكلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نقص هرمون النمو لدى البالغين هي حالة مزمنة تستمر مدى الحياة ويتعين على طبيبك علاجها على هذا الأساس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا استعملت كمية من سيزن أكبر مما يجب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حقنت كمية من سيزن أكبر من الموصوفة، فيجب عليك إخبار طبيبك لأن الأمر قد يستلزم تغيير الجرعة تغييرًا بسيطًا للتعويض عن ذلك. قد يؤدي حقن كمية أكبر من الموصوفة إلى تغيّرات في مستويات السكر في الدم مما قد يصيبك (أو يصيب طفلك) بالرجفة والدوار. اتصل بطبيبك في أقرب وقت ممكن في حال حدوث ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت استعمال سيزن</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا فوّتت جرعةً من سيزن، فأخبر طبيبك إذ أنه قد يكون من الضروري تغيير الجرعة بشكل بسيط للتعويض عن ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول سيزن</strong></p><p dir="RTL">لا تتوقف عن تناول سيزن بدون استشارة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا راودتك أيّ أسئلة إضافية حول استعمال هذا الدواء، فاطرحها على طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يسبب هذا الدواء آثاراً جانبية على الرغم من أنها لا تصيب جميع المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك على الفور إذا عانيت من صداع قوي ومتكرر مرتبط بالغثيان أو القيء أو اضطرابات الرؤية. فهذه أعراض لأثر جانبي يُدعى فرط الضغط الحميد داخل القحف (داخل الجمجمة) وهو غير شائع.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تُصنف الآثار الجانبية استنادًا إلى معدل حدوثها إلى الفئات التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الآثار الجانبية الشائعة جدا: قد تصيب أكثر من 1&nbsp;من كل 10&nbsp;أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شائعة: قد تؤثر على 1 من بين كل 10 أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غير شائعة: قد تؤثر على 1 من بين كل 100 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نادرة: قد تؤثر على 1 من بين كل 1000 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نادرة جدًا: قد تؤثر على 1 من بين كل 10000 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غير معروفة: يتعذّر تقدير معدل حدوثها من البيانات المتوفرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود الأفعال في مكان الحقن مثل الاحمرار، والحكة، والتورم، والطفح الجلدي، والشرى، والألم، والالتهاب، والنزيف، وتجمع غير طبيعي للدم خارج أحد الأوعية الدموية (ورم دموي). إذا أحسست أن ذلك بدأ يسبب لك مشكلة، فينبغي أن تستشير الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان موضعي للنسيج الدهني تحت الجلد، وهو ما يمكن تجنبه بتغيير مكان الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة النفق الرسغي لدى البالغين التي تتسم بشعور مستمر بالوخز، وإحساس بالحرقان، وألم و/أو تنميل في الأصابع وخاصة الإبهام والسبابة وفي بعض الأحيان أيضًا الوسطى والبنصر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس السوائل: الوذمة المحيطية (تورم)، وألم العضلات، والتنميل والنخز، وألم المفاصل، واضطرابات المفاصل لدى البالغين. تظهر هذه الآثار الجانبية عادة في مرحلة مبكرة من العلاج ولا تدوم طويلاً وتتوقف على الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع (حالات فردية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الضغط الحميد داخل القحف (زيادة في الضغط داخل الدماغ حول المخ تتسم بوجود صداع، وغثيان، وقيء، وازدواج الرؤية، وأعراض بصرية أخرى).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة النفق الرسغي لدى الأطفال التي تتسم بشعور مستمر بالوخز، وإحساس بالحرقان، وألم و/أو تنميل في الأصابع وخاصة الإبهام والسبابة وفي بعض الأحيان أيضًا الوسطى والبنصر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس السوائل: الوذمة المحيطية (تورم)، وألم العضلات، والتنميل والنخز، وألم المفاصل، واضطرابات المفاصل لدى الأطفال. تظهر هذه الآثار الجانبية عادة في مرحلة مبكرة من العلاج ولا تدوم طويلاً وتتوقف على الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخّم الثدي (قد يصيب ثدي واحد أو ثديين).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة جدًا:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُشاشة عظمة الفخذ العلوية المنزلقة (مشكلة في الورك تبدأ إذا انزلق الطرف النامي من عظمة الفخذ عن كرة مفصل الورك) ونخر رأس عظمة الفخذ اللاوعائي. يُرجى الاتصال بطبيبك أو الصيدلي إذا بدا على طفلك عرج غير مُفسّر وألم في الورك أو الركبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤدي العلاج بهرمون النمو إلى انخفاض مستويات هرمون الغدة الدرقية. بإمكان طبيبك اختبار ذلك، وسيصف العلاج الملائم إذا دعت الحاجة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية التي لا يُعرف معدل حدوثها:</strong></p><p dir="RTL">قد تتعرض (أو يتعرض طفلك) لردود فعل تحسسية نتيجة للعلاج بسيزن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتعرض (أو يتعرض طفلك) لارتفاع مستويات الأنسولين (فرط الإنسولينية) لأن خلايا العضلات والدهون والكبد لا تستجيب للأنسولين جيدًا في أثناء العلاج بهرمون النمو (مقاومة الأنسولين)، وقد يؤدي ذلك إلى ارتفاع في مستويات سكر الدم (فرط جلوكوز الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالات نادرة، تم الإبلاغ عن الإصابة بالتهاب البنكرياس لدى المرضى الذين يُعالجون بهرمون النمو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">لقد تم الإبلاغ عن حالات سرطان الدم (اللوكيميا) لدى أعداد قليلة من مرضى نقص هرمون النمو، وبعض هذه الحالات كانت تُعالج بدواء سوماتروبين. ولكن لا يوجد دليل على زيادة حدوث سرطان الدم (اللوكيميا) بين من أُعطوا هرمون النمو ولا توجد لديهم عوامل تجعلهم أكثر استعدادًا للإصابة به.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالات نادرة، يكون الجسم أجسامًا مضادة (نوع من البروتين الذي يساعد على حماية الجسم) لسوماتروبين. ولكن هذه الأجسام لا ترتبط بأيّ آثار جانبية ولا تؤثر عادةً على النمو.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفَظ هذا الدواء بعيداً عن مرأى الأطفال ومتناول أيديهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل سيزن بعد مرور تاريخ انتهاء الصلاحية المذكور على الخرطوشة بعد عبارة EXP، علمًا بأن تاريخ انتهاء الصلاحية هو آخر يوم في الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احفظ خرطوشة سيزن قبل استخدامها في الثلاجة (في درجة 2 إلى 8 مئوية) في عبوتها الأصلية لحمايتها من الضوء، ولكن لا تحفظه بالتجميد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب استعمال الخرطوشة في غضون 28 يومًا من تاريخ أول حقن منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد الحقنة الأولى، يجب تخزين خرطوشة سيزن أو محقنة &quot;إيزيبود&quot; الذاتية أو قلم حقن ألوتا المثبت بهما خرطوشة سيزن في الثلاجة (في درجة 2 إلى 8 درجات مئوية) لمدة أقصاها 28 يومًا. وخلال هذه المدة، يمكن الحفظ خارج الثلاجة لمدة تصل إلى 7 أيام متتالية على ألا تتجاوز درجة الحرارة 25 درجة مئوية. وفي حالة الحفظ خارج الثلاجة لمدة تصل إلى 7 أيام، يجب إعادة خرطوشة سيزن إلى الثلاجة واستخدامها في غضون 28 يومًا من تاريخ أول حقن منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عند استخدام محقنة &quot;إيزيبود&quot; الذاتية أو قلم حقن ألوتا، يجب ترك الخرطوشة في الجهاز. يجب حفظ الخرطوشة المستعملة بعيدًا من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أيّ أدوية في مياه الصرف أو النفايات المنزلية. اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد تستخدمها، لأن اتباع هذه الطريقة يساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفاعلة هي سوماتروبين (هرمون نمو بشري مأشوب) 6 ملغ<em>.</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي: سُكروز، بولوكسامير 188، فينول، حمض الستريك (لضبط درجة الحموضة)، هيدروكسيد الصوديوم (لضبط درجة الحموضة)، ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيزن 5.83 ملغ/مل عبارة عن محلول للحقن شفاف أو معتم قليلاً في خرطوشة معبأة مسبقًا (مصنوع من الزجاج من نوع 1) مزوّدة بسدادة كبس (من المطاط) وغطاء مرن (من الألومنيوم والمطاط) وتحتوي على قيمة ضئيلة تبلغ 1.03 مل من المحلول (6 ملغ من سوماتروبين). تحتوي العلبة على خرطوشة واحدة أو 5 خرطوشات. يتم تمييز الخرطوشة التي تحتوي على 6 ملغ من السوماتروبين بملصق ملون (أزرق).</p><p dir="RTL">&nbsp;</p><p>بعض أحجام العلب قد لا تتوفر في السوق</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل حق التسويق</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ميرك سيرونو المحدودة</p><p dir="RTL">بيدفونت كروس، طريق ستانويل</p><p dir="RTL">فيلتهام، ميدلسبره، TW14 8NX</p><p dir="RTL">المملكة المتحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المنتجة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">المناطق الصناعية دي مودوغنو،</p><p dir="RTL">&nbsp;70026 مودوغنو (باري)،</p><p dir="RTL">&nbsp;باري، إيطاليا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في ابريل 2020 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saizen 5.83 mg/ml solution for injection in cartridge
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each cartridge contains 1.03 ml solution (6 mg somatropin*).
*recombinant human growth hormone, produced by recombinant DNA technology in mammalian cells

One ml of solution contains 5.83 mg somatropin.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection in cartridge.
Clear to slightly opalescent solution with pH of 5.6-6.6 and osmolality 250-450 mOsm/kg.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Saizen is indicated in the treatment of:</p><p dir="ltr">&nbsp;</p><p dir="ltr">Children and adolescents:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth failure in children caused by decreased or absent secretion of endogenous growth hormone.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth failure in girls with gonadal dysgenesis (Turner syndrome), confirmed by chromosomal analysis.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth failure in prepubertal children due to chronic renal failure (CRF).</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth disturbance (current height SDS &lt;-2.5 and parental adjusted height SDS &lt;-1) in short children born small for gestational age (SGA) with a birth weight and/or length below -2&nbsp;SD, who failed to show catch-up growth (HV SDS &lt;0 during the last year) by 4&nbsp;years of age or later.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Adults:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Replacement therapy in adults with pronounced growth hormone deficiency as diagnosed by a single dynamic test for growth hormone deficiency. Patients must also fulfil the following criteria:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Childhood onset:<br />Patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with Saizen is started.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adult onset:<br />Patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Saizen 5.83&nbsp;mg/ml is intended for multiple dose use in an individual patient.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Posology</u></p><p dir="ltr">It is recommended that Saizen be administered at bedtime according to the following dosage:</p><p dir="ltr">&nbsp;</p><p dir="ltr">Children and adolescents:</p><p dir="ltr">Saizen<strong> </strong>dosage should be individualised for each patient based on body surface area or on body weight.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth failure due to inadequate endogenous growth hormone secretion:<br />0.7‑1.0&nbsp;mg/m<sup>2</sup> body surface area per day or 0.025‑0.035&nbsp;mg/kg body weight per day by subcutaneous administration.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth failure in girls due to gonadal dysgenesis (Turner syndrome):<br />1.4&nbsp;mg/m<sup>2</sup> body surface area per day or 0.045‑0.050&nbsp;mg/kg body weight per day by subcutaneous administration.<br />Concomitant therapy with non-androgenic anabolic steroids in patients with Turner syndrome can enhance the growth response.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth failure in prepubertal children due to chronic renal failure (CRF):<br />1.4&nbsp;mg/m<sup>2</sup> body surface area per day, approximately equal to 0.045‑0.050&nbsp;mg/kg body weight per day by subcutaneous administration.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth failure in short children born small for gestational age (SGA):<br />The recommended daily dose is 0.035&nbsp;mg/kg body weight (or 1&nbsp;mg/m<sup>2</sup>/day) by subcutaneous administration.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment should be discontinued when the patient has reached a satisfactory adult height or the epiphyses are fused.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For growth disturbance in short children born SGA, treatment is usually recommended until final height is reached. Treatment should be discontinued after the first year if height velocity SDS is below +1. Treatment should be discontinued when final height is reached (defined as height velocity &lt;2&nbsp;cm/year), and if confirmation is required if bone age is &gt;14&nbsp;years (girls) or &gt;16&nbsp;years (boys), corresponding to closure of the epiphyseal growth plates.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Adults:</p><p dir="ltr">Growth hormone deficiency in adults<br />At the start of somatropin therapy, low doses of 0.15‑0.3&nbsp;mg are recommended, given as a daily subcutaneous injection. The dose should be adjusted stepwise, controlled by Insulin-like Growth Factor&nbsp;1 (IGF‑1) values. The recommended final growth hormone dose seldom exceeds 1.0&nbsp;mg/day. In general the lowest efficacious dose should be administered.</p><p dir="ltr">Women may require higher doses than men, with men showing an increasing IGF-1 sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen therapy are under-treated while men are over-treated.</p><p dir="ltr">In older or overweight patients, lower doses may be necessary.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Patients with renal or hepatic impairment:</u></p><p dir="ltr">Currently available data are described in section 5.2 but no recommendation on a posology can be made.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Method of administration</u></p><p dir="ltr">For administration of the solution for injection of Saizen follow the instructions given in the package leaflet and in the instruction, manual provided with the selected injector: easypod auto-injector or aluetta pen injector.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">Intended users of easypod are primarily children starting from the age of 7 up to adults. Use of the devices by children should always be made under adult&rsquo;s supervision.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For instructions for handling please see section&nbsp;6.6.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Somatropin should not be used for growth promotion in children with closed epiphyses.

Somatropin must not be used when there is any evidence of activity of a tumour. Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting growth hormone therapy. Treatment should be discontinued if there is evidence of tumour growth.

Somatropin must not be used in case of proliferative or preproliferative diabetic retinopathy.

Patients with acute critical illness suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure or similar conditions should not be treated with somatropin.

In children with chronic renal disease, treatment with somatropin should be discontinued at renal transplantation.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Treatment should be carried out under the regular guidance of a physician who is experienced in the diagnosis and management of patients with growth hormone deficiency.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The maximum recommended daily dose should not be exceeded (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Neoplasm</u></p><p dir="ltr">Patients with an intra- or extracranial neoplasia in remission who are receiving treatment with growth hormone should be examined carefully and at regular intervals by the physician.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients with growth hormone deficiency secondary to an intracranial tumour should be examined frequently for progression or recurrence of the underlying disease process.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In childhood cancer survivors, an increased risk of a second neoplasm has been reported in patients treated with somatropin after their first neoplasm. Intracranial tumours, in particular meningiomas, in patients treated with radiation to the head for their first neoplasm, were the most common of these second neoplasms.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Prader-Willi syndrome</p><p dir="ltr">Somatropin is not indicated for the long-term treatment of paediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome, unless they also have a diagnosis of growth hormone deficiency. There have been reports of sleep apnoea and sudden death after initiating therapy with growth hormone in paediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnoea, or unidentified respiratory infection.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Leukaemia</p><p dir="ltr">Leukaemia has been reported in a small number of growth hormone deficiency patients, some of whom have been treated with somatropin. However, there is no evidence that leukaemia incidence is increased in growth hormone recipients without predisposition factors.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Insulin sensitivity</p><p dir="ltr">Because somatropin may reduce insulin sensitivity, patients should be monitored for evidence of glucose intolerance. For patients with diabetes mellitus, the insulin dose may require adjustment after somatropin-containing product therapy is instituted. Patients with diabetes or glucose intolerance should be monitored closely during somatropin therapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Retinopathy</u></p><p dir="ltr">Stable background retinopathy should not lead to discontinuation of somatropin replacement therapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Thyroid function</p><p dir="ltr">Growth hormone increases the extra thyroid conversion of T4 to T3 and may, as such, unmask incipient hypothyroidism. Monitoring of thyroid function should therefore be conducted in all patients. In patients with hypopituitarism, standard replacement therapy must be closely monitored when somatropin therapy is administered.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Benign intracranial hypertension</p><p dir="ltr">In case of severe or recurrent headache, visual problems, nausea and/or vomiting, funduscopy for papilloedema is recommended. If papilloedema is confirmed a diagnosis of benign intracranial hypertension (or <em>pseudotumor cerebri</em>) should be considered and if appropriate, Saizen treatment should be discontinued. At present there is insufficient evidence to guide clinical decision-making in patients with resolved intracranial hypertension. If growth hormone treatment is restarted, careful monitoring for symptoms of intracranial hypertension is necessary.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Pancreatitis</u></p><p dir="ltr">Although rare, pancreatitis should be considered in somatropin-treated patients, especially children who develop abdominal pain.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Scoliosis</u></p><p dir="ltr">Scoliosis is known to be more frequent in some of the patient groups treated with somatropin for example Turner syndrome. In addition, rapid growth in any child can cause progression of scoliosis. Somatropin has not been shown to increase the incidence or severity of scoliosis. Signs of scoliosis should be monitored during treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Antibodies</p><p dir="ltr">As with all somatropin containing products, a small percentage of patients may develop antibodies to somatropin. The binding capacity of these antibodies is low and there is no effect on growth rate.<em> </em>Testing for antibodies to somatropin should be carried out in any patient who fails to respond to therapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Slipped capital femoral epiphysis</u></p><p dir="ltr">Slipped capital femoral epiphysis is often associated with endocrine disorders such as growth hormone deficiency and hypothyroidism, and with growth spurts. In children treated with growth hormone, slipped capital femoral epiphysis may either be due to underlying endocrine disorders or to the increased growth velocity caused by the treatment. Growth spurts may increase the risk of joint-related problems, the hip joint being under particular strain during the prepubertal growth spurt. Physicians and parents should be alert to the development of a limp or complaints of hip or knee pain in children treated with Saizen.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Growth failure due to chronic renal failure</u></p><p dir="ltr">Patients with growth failure due to chronic renal failure should be examined periodically for evidence of progression of renal osteodystrophy. Slipped capital femoral epiphysis or avascular necrosis of the femoral head may be seen in children with advanced renal osteodystrophy and it is uncertain whether these problems are affected by growth hormone therapy. X‑rays of the hip should be obtained prior to initiating therapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In children with chronic renal failure, renal function should have decreased to below 50% of normal before therapy is instituted. To verify the growth disturbance, growth should have been followed for a year before institution of therapy. Conservative treatment for renal insufficiency (which includes control of acidosis, hyperparathyroidism and nutritional status for one year prior to the treatment) should have been established and should be maintained during treatment. Treatment should be discontinued at the time of renal transplantation.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Children born small for gestational age</u></p><p dir="ltr">In short children born SGA other medical reasons or treatments that could explain growth disturbance should be ruled out before starting treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For SGA patients it is recommended to measure fasting insulin and blood glucose before start of treatment and annually thereafter. In patients with increased risk for diabetes mellitus (e.g. familial history of diabetes, obesity, increased body mass index, severe insulin resistance, <em>acanthosis nigricans</em>) oral glucose tolerance testing (OGTT) should be performed. If overt diabetes occurs, growth hormone should not be administered.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For SGA patients it is recommended to measure IGF-I level before start of treatment and twice a year thereafter. If on repeated measurements IGF-I levels exceed +2&nbsp;SD compared to references for age and pubertal status, the IGF-I/IGFBP‑3 ratio could be taken into account to consider dose adjustment.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Experience in initiating treatment in SGA patients near onset of puberty is limited. It is therefore not recommended to initiate treatment near onset of puberty. Experience with SGA patients with Silver‑Russell syndrome is limited.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Some of the height gain obtained with treating short children born SGA with somatropin may be lost if treatment is stopped before final height is reached.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Fluid retention</u></p><p dir="ltr">Fluid retention is expected during growth hormone replacement therapy in adults.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In case of persistent oedema or severe paraesthesia the dosage should be decreased in order to avoid the development of carpal tunnel syndrome.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Acute critical illness</u></p><p dir="ltr">In all patients developing acute critical illness, the possible benefit of treatment with somatropin must be weighed against the potential risk involved.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Interaction with glucocorticoids</u></p><p dir="ltr">Initiation of growth hormone replacement may unmask secondary adrenal insufficiency in some patients by reducing the activity of 11&beta;-hydroxysteroid dehydrogenase, type 1 (11&beta;-HSD1), an enzyme converting inactive cortisone to cortisol and glucocorticoid replacement may be required. Initiation of somatropin in patients receiving glucocorticoid replacement therapy may lead to manifestation of cortisol deficiency. Adjustment of glucocorticoid dose may be required (see section&nbsp;4.5).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Use with oral oestrogen therapy</u></p><p dir="ltr">If a woman taking somatropin begins oral oestrogen therapy, the dose of somatropin may need to be increased to maintain the serum IGF-1 levels within the normal age-appropriate range. Conversely, if a woman on somatropin discontinues oral oestrogen therapy, the dose of somatropin may need to be reduced to avoid excess of growth hormone and/or side effects (see section&nbsp;4.5).</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>General</u></p><p dir="ltr">The injection site should be varied to prevent lipoatrophy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Growth hormone deficiency in the adult is a lifelong condition and should be treated accordingly, however experience with patients over sixty years and experience with prolonged treatment is limited.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Excipients</u></p><p dir="ltr">This medicinal product contains less than 1 mmol sodium (23 mg) per cartridge, i.e. essentially &lsquo;sodium-free&rsquo;.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Concomitant treatment with glucocorticoids inhibits the growth-promoting effects of somatropin containing products. Patients with ACTH deficiency should have their glucocorticoid replacement therapy carefully adjusted to avoid any inhibitory effect on growth hormone.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Growth hormone decreases the conversion of cortisone to cortisol and may unmask previously undiscovered central hypoadrenalism or render low glucocorticoid replacement doses ineffective (see section&nbsp;4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In women on oral oestrogen replacement, a higher dose of growth hormone may be required to achieve the treatment goal (see section&nbsp;4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Data from an interaction study performed in growth hormone deficient adults, suggests that somatropin administration may increase the clearance of compounds known to be metabolised by cytochrome P450 isoenzymes. The clearance of compounds metabolised by cytochrome&nbsp;P450&nbsp;3A4 (e.g. sex steroids, corticosteroids, anticonvulsants and cyclosporine) may be especially increased resulting in lower plasma levels of these compounds. The clinical significance of this is unknown</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p dir="ltr">Pregnancy</p><p dir="ltr">No clinical data on exposed pregnancies are available. From the reproductive studies performed in animals with somatropin containing products, there is no evidence of an increased risk of adverse reactions for the embryo or foetus (see section 5.3). However, somatropin containing products are not recommended during pregnancy and in woman of childbearing potential not using contraception.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Breastfeeding</p><p dir="ltr">There have been no clinical studies conducted with somatropin in breast-feeding women. It is not known whether somatropin is excreted in human milk. Therefore caution should be exercised when somatropin is administered to breast-feeding women.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Fertility</u></p><p dir="ltr">Non-clinical toxicity studies showed that somatropin did not induce adverse effects on male and female fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">&nbsp;</p><p dir="ltr">Somatropin-containing products have no influence on the ability to drive and use machines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">&nbsp;</p><p dir="ltr">Up to 10% of patients may experience redness and itching at the site of injection.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Fluid retention is expected during growth hormone replacement therapy in adults. Oedema, joint swelling, arthralgias, myalgias and paraesthesias may be clinical manifestations of fluid retention. However, these symptoms / signs are usually transient and dose dependent.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Adult patients with growth hormone deficiency, following diagnosis of growth hormone deficiency in childhood, reported side-effects less frequently than those with adult onset growth hormone deficiency.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Antibodies to somatropin can form in a small percentage of patients; to date the antibodies have been of low binding capacity and have not been associated with growth attenuation except in patients with gene deletions. In very rare instances, where short stature is due to deletion of the growth hormone gene complex, treatment with growth hormone may induce growth attenuating antibodies.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Leukaemia has been reported in a small number of growth hormone deficiency patients, some of whom have been treated with somatropin. However, there is no evidence that leukaemia incidence is increased in growth hormone recipients without predisposing factors.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The following definitions apply to the frequency terminology used hereafter: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), frequency not known (cannot be estimated from the available data).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Common<br />&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon<br />&nbsp;</p></td><td style="vertical-align:top"><p>Very rare<br />&nbsp;</p></td><td style="vertical-align:top"><p>Frequency not known</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache (isolated), carpal tunnel syndrome (in adults)</p></td><td style="vertical-align:top"><p>Idiopathic intracranial hypertension (benign intracranial hypertension),<br />carpal tunnel syndrome (in children)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Slipped capital femoral epiphysis (<em>Epiphysiolysis capitis femoris</em>), or avascular necrosis of the femoral head</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Localised and generalised hypersensitivity reactions</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypothyroidism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>In adults: Fluid retention: peripheral oedema, stiffness, arthralgia, myalgia, paraesthesia</p></td><td style="vertical-align:top"><p>In children: Fluid retention: peripheral oedema, stiffness, arthralgia, myalgia, paraesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insulin resistance can result in hyperinsulinism and in rare cases in hyperglycaemia</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gynaecomastia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Injection site reactions,<br />localised lipoatrophy, which can be avoided by varying the site of injection</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr></tbody></table><p dir="ltr"><u>&nbsp;</u>&nbsp;To report any side effect(s):</p><ul dir="ltr"><li><strong><em>Saudi Arabia: </em></strong></li></ul><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p style="text-align:right">&nbsp;</p><p style="text-align:right"><strong>- </strong>The National Pharmacovigilance Centre (NPC)</p><ul><li style="text-align: right;">Fax: +966-11-205-7662</li><li style="text-align: right;">Toll free phone: 19999</li><li style="text-align: right;">E-mail: npc.drug@sfda.gov.sa&nbsp;&nbsp;</li><li style="text-align: right;">Website: https://ade.sfda.gov.sa/</li></ul><p style="text-align:right">&nbsp;</p></td></tr></tbody></table><p dir="ltr" style="text-align:right">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p dir="ltr">&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Exceeding the recommended doses can cause side effects. Overdose can lead to hypoglycaemia and subsequently to hyperglycaemia. Moreover, somatropin overdose is likely to cause manifestations of fluid retention.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Anterior pituitary lobe hormones and analogues, ATC code: H01AC01</p><p dir="ltr">&nbsp;</p><p dir="ltr">Saizen contains recombinant human growth hormone produced by genetically engineered mammalian cells.</p><p dir="ltr">&nbsp;</p><p dir="ltr">It is a peptide of 191&nbsp;amino acids identical to human pituitary growth hormone with respect to amino acid sequence and composition as well as peptide map, isoelectric point, molecular weight, isomeric structure and bioactivity.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Growth hormone is synthesised in a transformed murine cell line that has been modified by the addition of the gene for pituitary growth hormone.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Saizen is an anabolic and anticatabolic agent which exerts effects not only on growth but also on body composition and metabolism. It interacts with specific receptors on a variety of cell types including myocytes, hepatocytes, adipocytes, lymphocytes and hematopoietic cells. Some, but not all of its effects are mediated through another class of hormones known as somatomedins (IGF‑1 and IGF‑2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Depending on the dose, the administration of Saizen elicits a rise in IGF‑1, IGFBP‑3, non-esterified fatty acids and glycerol, a decrease in blood urea, and decreases in urinary nitrogen, sodium and potassium excretion. The duration of the increase in growth hormone levels may play a role in determining the magnitude of the effects. A relative saturation of the effects of Saizen at high doses is probable. This is not the case for glycaemia and urinary C‑peptide excretion, which are significantly elevated after high doses (20&nbsp;mg).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In a randomised clinical trial, three years treatment of pre-pubertal short children born SGA with a dose of 0.067&nbsp;mg/kg/day resulted in a mean gain of +1.8 height-SDS. In those children who did not receive treatment beyond 3 years, part of the treatment benefit was lost, but the patients retained a significant gain of +0.7 height-SDS at final height (p&lt;0.01 compared to baseline). Patients who received a second treatment course after a variable period of observation experienced a total gain of +1.3 height-SDS (p&lt;0.001 compared to baseline) at final height. (The mean cumulative treatment duration in the latter group was 6.1&nbsp;years). The gain in height-SDS (+1.3&plusmn;1.1) at final height in this group was significantly (p&lt;0.05) different from the gain in height-SDS obtained in the first group (+0.7&plusmn;0.8) that received only 3.0&nbsp;years of treatment on average.</p><p dir="ltr">&nbsp;</p><p dir="ltr">A second clinical trial investigated two different dose regimens over four years. One group was treated with 0.067&nbsp;mg/kg/day for 2&nbsp;years and then observed without treatment for 2&nbsp;years. The second group received 0.067&nbsp;mg/kg/day in the first and third year and no treatment in the second and fourth&nbsp;year. Either treatment regimen resulted in a cumulative administered dose of 0.033&nbsp;mg/kg/day over the four-year study period. Both groups showed a comparable acceleration of growth and a significant improvement of +1.55 (p&lt;0.0001) and + 1.43 (p&lt;0.0001) height-SDS respectively at the end of the four-year study period. Long-term safety data are still limited.</p><p dir="ltr"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The pharmacokinetics of Saizen are linear at least up to doses of 8&nbsp;IU (2.67&nbsp;mg). At higher doses (60&nbsp;IU/20&nbsp;mg) some degree of non-linearity cannot be ruled out, however with no clinical relevance.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Following intravenous administration in healthy volunteers the volume of distribution at steady-state is around 7&nbsp;L, total metabolic clearance is around 15&nbsp;L/h while the renal clearance is negligible, and the drug exhibits an elimination half-life of 20 to 35&nbsp;min.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Following single-dose subcutaneous and intramuscular administration of Saizen, the apparent terminal half-life is much longer, around 2 to 4&nbsp;hours. This is due to a rate limiting absorption process.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The absolute bioavailability of both routes is 70-90%.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Maximum serum growth hormone concentrations are reached after approximately 4&nbsp;hours and serum growth hormone levels return to baseline within 24 hours, indicating that no accumulation of growth hormone will occur during repeated administrations.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Saizen solutions for injection (5.83 and 8&nbsp;mg/ml) administered subcutaneously have been shown to be bioequivalent versus the 8&nbsp;mg freeze-dried formulation.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Renal impairment</u></p><p dir="ltr">Somatropin clearance is known to be reduced in patients with renal impairment. However, the clinical significance of this finding is unknown.</p><p dir="ltr">For prepubertal children with growth failure due to chronic renal failure a specific posology is recommended (see section 4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Hepatic impairment</u></p><p dir="ltr">Somatropin clearance is known to be reduced in patients with hepatic impairment. However, as Saizen has not been studied in patients with hepatic impairment, the clinical significance of this finding is unknown.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">In animal studies, Saizen solution for injection was shown to be very well tolerated locally when administered subcutaneously in animals at a concentration of 8 mg/m1 and volumes of 1 ml/site.</p><p dir="ltr">Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, single and repeated dose toxicity and genotoxicity. Formal carcinogenicity studies were not performed. This is justified, given the proteinous nature of the drug substance and the negative outcome of the genotoxicity testing. The potential effects of somatropin on the growth of pre-existing tumours have been evaluated through i<em>n vitro </em>and <em>in vivo </em>experiments including rats at doses of 15&nbsp;mg/kg/day (over 120 times the usual maximum daily clinical dose in adults and 60 times in children) which have shown that recombinant human growth hormone is not expected to cause or stimulate tumours in patients.</p><p dir="ltr">Reproductive toxicology studies performed in rats and rabbits at doses up to 3.3&nbsp;mg/kg/day (over 25 times the usual maximum daily clinical dose in adults and 14 times in children) did not indicate adverse effects on embryo-foetal development nor on the F1 generation development or fertility. The fertility of adult male and female rats was not impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Sucrose 77.300 mg</p><p dir="ltr">Poloxamer 188 (2.100 mg)</p><p dir="ltr">Phenol 3.800 mg</p><p dir="ltr">Citric acid (for pH adjustment) QS</p><p dir="ltr">Citrate Buffer 10 MM (QS)</p><p dir="ltr">Water for injection 1.03 ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months

Chemical, physical and microbiological in-use stability has been demonstrated for a total of 28 days at 2°C to 8°C.

Other in-use storage times and conditions are the responsibility of the user.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store the unused Saizen cartridge in a refrigerator (2&deg;C‑8&deg;C). Do not freeze. Store in the original package to protect from light.</p><p dir="ltr">&nbsp;</p><p dir="ltr">After first injection, the Saizen cartridge, the easypod auto-injector containing the Saizen cartridge or the aluetta pen injector containing the Saizen cartridge has to be stored in a refrigerator (2&deg;C‑8&deg;C) for a maximum of 28 days.</p><p dir="ltr">&nbsp;</p><p dir="ltr">When using the easypod auto-injector or the aluetta pen injector, the cartridge is kept in the device. Protect the used cartridge from light.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The container is a colourless type&nbsp;I glass cartridge with closure consisting of a Bromo butyl rubber plunger stopper and an aluminium crimp cap with a Bromo butyl rubber single inlay. The glass cartridge containing 6 mg somatropin is marked with a coloured label (blue).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Saizen 5.83&nbsp;mg/ml solution for injection in cartridge is available in the following pack sizes:</p><p dir="ltr">&nbsp;</p><p dir="ltr">Pack of 1&nbsp;cartridge, each containing 1.03&nbsp;ml solution (6&nbsp;mg somatropin).</p><p dir="ltr">Pack of 5&nbsp;cartridges, each containing 1.03&nbsp;ml solution (6&nbsp;mg somatropin)</p><p dir="ltr">&nbsp;</p><p dir="ltr">Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The container is a colourless type&nbsp;I glass cartridge with closure consisting of a Bromo butyl rubber plunger stopper and an aluminium crimp cap with a Bromo butyl rubber single inlay. The glass cartridge containing 6 mg somatropin is marked with a coloured label (blue).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Saizen 5.83&nbsp;mg/ml solution for injection in cartridge is available in the following pack sizes:</p><p dir="ltr">&nbsp;</p><p dir="ltr">Pack of 1&nbsp;cartridge, each containing 1.03&nbsp;ml solution (6&nbsp;mg somatropin).</p><p dir="ltr">Pack of 5&nbsp;cartridges, each containing 1.03&nbsp;ml solution (6&nbsp;mg somatropin)</p><p dir="ltr">&nbsp;</p><p dir="ltr">Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Merck Serono Limited 
Bedfont Cross, Stanwell road
Felltham, Middlesex, TW14 8NX
Felltham, United Kingdom

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04 Jan 2021 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>